Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma

@article{Luster2009ClinicalVO,
  title={Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma},
  author={M. Luster and W. Karges and Katrin Zeich and S. Pauls and F. Verburg and H. Dralle and G. Glatting and A. Buck and C. Solbach and B. Neumaier and S. Reske and F. Mottaghy},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2009},
  volume={37},
  pages={484-493}
}
PurposeIn detecting pheochromocytoma (PHEO), positron emission tomography (PET) with the radiolabelled amine precursor 18F-fluorodihydroxyphenylalanine (18F-DOPA) offers excellent specificity, while computed tomography (CT) provides high sensitivity and ability to localize lesions; therefore, the combination of these modalities could be advantageous in this setting. The aim of this study was to investigate whether combined 18F-DOPA PET/CT more accurately detects and localizes PHEO lesions than… Expand
(18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.
TLDR
In the assessment of pheochromocytoma, the combination of (18)F-DOPA PET with MRI is superior to MRI-alone. Expand
Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma
TLDR
These data support the superiority of 18F-DOPA PET-CT over 123I-MIBG scintigraphy to assess disease extension in patients with recurrent paraganglioma; however, in cases with inoperable disease, 123I -MIBG maintains a unique role in allowing the selection of patients suitable for 131I- MIBG therapy. Expand
Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis
TLDR
A significant increase in sensitivity of 18F-DOPA PET or PET/CT was observed when a sub-analysis excluding patients with succinate dehydrogenase subunit B (SDHB) gene mutations was performed, suggesting that SDHB gene mutations could influence 18F/PET/CT diagnostic performance. Expand
18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours
TLDR
Evaluating the biodist distribution pattern and normal variants of 18F-DOPA in a cohort of patients with neuroendocrine tumours using semiquantitative analysis may provide useful information in understanding the physiologic biodistribution of DOPA and its variants. Expand
Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and nonfluorodeoxyglucose tracers
TLDR
The aim of this review article is to provide an overview of the role of 18F-FDG and newer positron-emitting radiopharmaceuticals in the evaluation of adrenal and neuroendocrine tumors. Expand
Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis
TLDR
Evidence-based data show that [18F]DOPA PET and PET/CT are accurate methods in patients with proven or suspected NETs, and large multicenter studies are necessary to substantiate the diagnostic accuracy of these methods. Expand
18F-DOPA PET/CT in Neuroblastoma: Comparison of Conventional Imaging With CT/MR
TLDR
In this study, 18F-DOPA PET/CT results more accurate than CT/MR in advanced stage NB therefore should be taken into consideration for the diagnostic workup of these patients. Expand
Adrenal tracer uptake by 18F-FDOPA PET/CT in patients with pheochromocytoma and controls
TLDR
18F-FDOPA PET/CT distinguishes pheochromocytoma from normal adrenal glands with the highest diagnostic accuracy when combining the SUVmax of the affected adrenal gland with the difference in SUVmax between affected and normal adrenAL gland. Expand
18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma
TLDR
18F-FDOPA PET/CT should be considered as the first-line functional imaging modality for diagnostic or follow-up evaluations for these patients with rare, but clinically important, MAX-related PHEOs. Expand
Quantitative analysis of normal and pathologic adrenal glands with 18F-FDOPA PET/CT: focus on pheochromocytomas
TLDR
The high affinity of 18F-FDOPA for secreting or nonsecreting pheochromocytoma is confirmed, and within a series of various adrenal glands, only these tumors presented a significant increased uptake compared with normal Adrenal glands. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Pheochromocytomas: detection with 18F DOPA whole body PET--initial results..
TLDR
F DOPA PET is highly sensitive and specific for detection of pheochromocytomas and has potential as the functional imaging method of the future. Expand
18F-FDOPA PET and PET/CT Accurately Localize Pheochromocytomas
TLDR
18F-FDOPA PET and PET/CT are highly sensitive and specific tools that can provide additional independent information for diagnosis and localization of benign and malignant pheochromocytomas. Expand
Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET.
TLDR
FDG PET is especially useful in defining the distribution of those pheochromocytomas that fail to concentrate MIBG, especially in patients whose tumors concentrated both agents. Expand
18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels
TLDR
18F-DOPA PET is a new functional imaging procedure for medullary thyroid carcinoma that seems to provide better results than SRS and 18F-FDG PET, and is a useful supplement to morphological diagnostic imaging, improving lymph node staging and enabling a more specific diagnosis of primary tumour and local recurrence. Expand
[11C]Metahydroxyephedrine and [18F]Fluorodeoxyglucose Positron Emission Tomography Improve Clinical Decision Making in Suspected Pheochromocytoma
TLDR
PET scanning for pheochromocytoma offers improved quality and resolution over current diagnostic approaches and may significantly influence the clinical management of patients with a suspicion of these tumors. Expand
6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
TLDR
To localize tumors causing catecholamine excess, (18)F-DOPA PET is superior to (123)I-MIBG scintigraphy and CT/MRI. Expand
Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors.
TLDR
18F dopa PET is a promising procedure and useful supplement to morphologic methods in diagnostic imaging of gastrointestinal carcinoid tumors and best localization of primary tumors and lymph node staging. Expand
The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT
TLDR
DOPAPET-CT showed superior results to FDG PET-CT in the preoperative and follow-up assessment of MTC patients and is recommended as a one-stop diagnostic procedure to provide both functional and morphological data in order to select those patients who may benefit from (re-)operation with curative intent as well as guiding further surgical procedures. Expand
PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma.
TLDR
PET scanning with 11C-HED localizes pheochromocytoma using a specifically designed radiotracer and advanced imaging technology, and has promise for locating the more elusive tumors. Expand
Pheochromocytomas: detection with 11C hydroxyephedrine PET.
TLDR
HED PET is useful in the detection of pheochromocytomas, providing a high level of accuracy, and is validated with histologic evaluation and clinical follow-up. Expand
...
1
2
3
4
...